6.
Mikkelsen K, Sirisarn W, Alharbi O, Alharbi M, Liu H, Nohr-Meldgaard K
. The Novel Membrane-Associated Auxiliary Factors AuxA and AuxB Modulate β-lactam Resistance in MRSA by stabilizing Lipoteichoic Acids. Int J Antimicrob Agents. 2021; 57(3):106283.
DOI: 10.1016/j.ijantimicag.2021.106283.
View
7.
Hutchings M, Truman A, Wilkinson B
. Antibiotics: past, present and future. Curr Opin Microbiol. 2019; 51:72-80.
DOI: 10.1016/j.mib.2019.10.008.
View
8.
Pappas P, Kauffman C, Andes D, Clancy C, Marr K, Ostrosky-Zeichner L
. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2015; 62(4):e1-50.
PMC: 4725385.
DOI: 10.1093/cid/civ933.
View
9.
von Lilienfeld-Toal M, Wagener J, Einsele H, Cornely O, Kurzai O
. Invasive Fungal Infection. Dtsch Arztebl Int. 2019; 116(16):271-278.
PMC: 6549129.
DOI: 10.3238/arztebl.2019.0271.
View
10.
Jacobs S, Zagaliotis P, Walsh T
. Novel antifungal agents in clinical trials. F1000Res. 2022; 10:507.
PMC: 8787557.
DOI: 10.12688/f1000research.28327.2.
View
11.
de Oliveira Santos G, Vasconcelos C, Lopes A, de Sousa Cartagenes M, Filho A, do Nascimento F
. Infections and Therapeutic Strategies: Mechanisms of Action for Traditional and Alternative Agents. Front Microbiol. 2018; 9:1351.
PMC: 6038711.
DOI: 10.3389/fmicb.2018.01351.
View
12.
Mota Fernandes C, Dasilva D, Haranahalli K, McCarthy J, Mallamo J, Ojima I
. The Future of Antifungal Drug Therapy: Novel Compounds and Targets. Antimicrob Agents Chemother. 2020; 65(2).
PMC: 7848987.
DOI: 10.1128/AAC.01719-20.
View
13.
Cheng G, Sa W, Cao C, Guo L, Hao H, Liu Z
. Quinoxaline 1,4-di-N-Oxides: Biological Activities and Mechanisms of Actions. Front Pharmacol. 2016; 7:64.
PMC: 4800186.
DOI: 10.3389/fphar.2016.00064.
View
14.
Mayer F, Kronstad J
. Discovery of a Novel Antifungal Agent in the Pathogen Box. mSphere. 2017; 2(2).
PMC: 5390095.
DOI: 10.1128/mSphere.00120-17.
View
15.
Miceli M, Kauffman C
. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent. Clin Infect Dis. 2015; 61(10):1558-65.
DOI: 10.1093/cid/civ571.
View
16.
Parente-Rocha J, Bailao A, Amaral A, Taborda C, Paccez J, Borges C
. Antifungal Resistance, Metabolic Routes as Drug Targets, and New Antifungal Agents: An Overview about Endemic Dimorphic Fungi. Mediators Inflamm. 2017; 2017:9870679.
PMC: 5485324.
DOI: 10.1155/2017/9870679.
View
17.
Tan C, Therien A, Lu J, Lee S, Caron A, Gill C
. Restoring methicillin-resistant Staphylococcus aureus susceptibility to β-lactam antibiotics. Sci Transl Med. 2012; 4(126):126ra35.
DOI: 10.1126/scitranslmed.3003592.
View
18.
Ashley E
. Antifungal Drugs: Special Problems Treating Central Nervous System Infections. J Fungi (Basel). 2019; 5(4).
PMC: 6958367.
DOI: 10.3390/jof5040097.
View
19.
Gonzales P, Pesesky M, Bouley R, Ballard A, Biddy B, Suckow M
. Synergistic, collaterally sensitive β-lactam combinations suppress resistance in MRSA. Nat Chem Biol. 2015; 11(11):855-61.
PMC: 4618095.
DOI: 10.1038/nchembio.1911.
View
20.
Takakura N, Sato Y, Ishibashi H, Oshima H, Uchida K, Yamaguchi H
. A novel murine model of oral candidiasis with local symptoms characteristic of oral thrush. Microbiol Immunol. 2003; 47(5):321-6.
DOI: 10.1111/j.1348-0421.2003.tb03403.x.
View